Proteogenix는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
제품 번호
PX-TA1637
제품 특징
Product name | Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade |
---|---|
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Aliases /Synonyms | Sotrovimab ,,Spike glycoprotein,anti-Spike glycoprotein |
Reference | PX-TA1637 |
Note | For research use only. Not suitable for human use. |
Isotype | Human IgG |
Clonality | Monoclonal Antibody |
Sotrovimab is a neutralizing monoclonal antibody with an activity against SARS-CoV-2 virus in humans. It has been commercialized as XEVUDY by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is able to bind with Spike protein, which is responsible of the pathogenicity of the Severe Acute Respiratory Syndrome- Coronavirus( SARS-CoV-2).
FDA and EMA have very recently given their approvals for the marketing of Sotrovimab as a treatment against some severe forms of COVID. The epitope targeted by this neutralizing antibody is not mutated in the different variants of SARS-CoV-2 of concern.
Spike glycoprotein is a transmembrane viral fusion protein. It is known to be paramount in the binding of the virus to the cell during infection process. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Sotrovimab biosimilar is a dual-action antibody, which is able to to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs. Proteogenix offers this product for research use only. Sotrovimab is a human-origin monoclonal antibody expressed in a mammalian system (Chinese Hamster Ovaries-CHO).
QC & Validation Data
Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Immobilized RBD Domain (cat. No.PX-COV-P046) at 0.5µg/mL (100µL/well) can bind to Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb (cat. No.PX-TA1637) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Publications
ProteoGenix의 모든 제품들을 만나보세요!
Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"